Published: Apr 02, 2021
SAN DIEGO, Calif., April 2, 2021 /PRNewswire/ Together with scientists from the University of California, San Diego (UCSD), Global Cancer Technology (GCT) and the renowned Barrow Neurological Institute, pre-clinical studies have begun towards the commercialization of a new glioblastoma treatment. Glioblastoma is a rare cancer, occurring in fewer than one in 10,000 cases; however, it is among the most aggressive and lethal cancers. Fewer than 25% of those diagnosed will survive one year and fewer than 5% survive five years. Incidence in men is slightly higher than in women with the average age of diagnosis around 60. Glioblastoma is on the rise where contributing factors including ionizing radiation, air pollution, and an aging population. Each year, more than 17,000 Americans die from this incurable disease.
A Novel Treatment Modality for COVID-19: Global Cancer Technology is Developing a Nanoparticle Which May Selectively Target, Bind and Inactivate Coronavirus Virions PR.com
2020-12-30
San Francisco, CA, December 30, 2020 (PR.com) COVID-19 is relentless, showing no signs of abating any time soon. December 2020 is the deadliest month on record since the pandemic began with more than 63,000 Americans deceased before Christmas as a result of the disease. Worldwide, more than 81 million cases and 1.8 million deaths have been reported. Innovative treatments are critically needed to support healthcare workers and hospitals that continue to operate at or beyond capacity. Global Cancer Technology (GCT) has licensed a technology developed at the UCSD Medical System for a novel treatment that is designed to selectively target and inactivate coronavirus virions.